Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer

被引：10

作者：

Liu, Yi-Fu ^{[1
]}

Fu, Sheng-Qiang ^{[1
]}

Yan, Yu-Chang ^{[1
]}

Gong, Bin-Bin ^{[1
]}

Xie, Wen-Jie ^{[1
]}

Yang, Xiao-Rong ^{[1
]}

Sun, Ting ^{[1
]}

Ma, Ming ^{[1
]}

机构：

[1] Nanchang Univ, Affiliated Hosp 1, Dept Urol, Nanchang 330000, Jiangxi, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2021年 / 15卷

关键词：

gonadotropin-releasing hormone; prostate cancer; degarelix; relugolix; ANDROGEN-DEPRIVATION THERAPY; ANTIANDROGEN FLARE PROTECTION; URINARY-TRACT SYMPTOMS; III EXTENSION TRIAL; OF-LIFE IMPROVEMENT; OPEN-LABEL; GNRH ANTAGONIST; PHASE-II; JAPANESE PATIENTS; 1-ARM CROSSOVER;

D O I：

10.2147/DDDT.S291369

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Gonadotropin-releasing hormone (GnRH) receptor agonists are still the most commonly used androgen deprivation treatment (ADT) drugs for prostate cancer in clinical practice. Currently, the GnRH receptor antagonists used for endocrine therapy for prostate cancer primarily include degarelix and relugolix (TAK-385). The former is administered by subcutaneous injection, while the latter is an oral drug. Compared to GnRH agonists, GnRH antagonists reduce serum testosterone levels more rapidly without an initial testosterone surge or subsequent microsurges. This review focuses on the mechanism of action of GnRH antagonists and agonists, the developmental history of GnRH antagonists, and emerging data from clinical studies of the two antagonists used as endocrine therapy for prostate cancer.

引用

页码：639 / 649

页数：11

共 50 条

[11] Treatment of prostate cancer with gonadotropin-releasing hormone analogue: Effect on lipoprotein[a]
Arrer, E
Jungwirth, A
Mack, D
Frick, J
Patsch, W
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (07): : 2508 - 2511
[12] Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer
George, Daniel J.
Dearnaley, David P.
FUTURE ONCOLOGY, 2021, 17 (33) : 4431 - 4446
[13] Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer
Anderson, John
FUTURE ONCOLOGY, 2009, 5 (04) : 433 - 443
[14] Gonadotropin-releasing hormone in apoptosis of prostate cancer cells
Kraus, S
Naor, Z
Seger, R
CANCER LETTERS, 2006, 234 (02) : 109 - 123
[15] Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas
Neblett II, Michael F.
Stewart, Elizabeth A.
OBSTETRICS AND GYNECOLOGY, 2023, 141 (05): : 901 - 910
[16] GONADOTROPIN-RELEASING HORMONE ANTAGONISTS AS TREATMENT FOR AUTOIMMUNE PROGESTERONE DERMATITIS
Luu, J.
Reddy, P.
Kumar, M.
Tsai, L.
White, A.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2024, 133 (06) : S207 - S207
[17] CLINICAL-APPLICATIONS OF GONADOTROPIN-RELEASING HORMONE AND GONADOTROPIN-RELEASING HORMONE ANALOGS
YEN, SSC
FERTILITY AND STERILITY, 1983, 39 (03) : 257 - 266
[18] Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor in sheep spinal cord
Dolan, S
Evans, NP
Richter, TA
Nolan, AM
NEUROSCIENCE LETTERS, 2003, 346 (1-2) : 120 - 122
[19] Gonadotropin-Releasing Hormone Antagonists Revolutionizing Gynecology
Esencan, Ecem
Taylor, Hugh S.
OBSTETRICS AND GYNECOLOGY, 2022, 140 (06): : 917 - 919
[20] Negative regulation of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor gene expression by a gonadotropin-releasing hormone agonist in the rat hypothalamus
Han, YG
Kang, SS
Seong, JY
Geum, D
Suh, YH
Kim, K
JOURNAL OF NEUROENDOCRINOLOGY, 1999, 11 (03) : 195 - 201

← 1 2 3 4 5 →